Complex Diagnosis of Myeloid Neoplasms in Regional Oncological Centers

Authors

  • D.F. Gluzman Institute of Experimental Pathology, Oncology and Radiobiology. RE Kavetsky NAS of Ukraine, Kyiv
  • L.M. Sklyarenko Institute of Experimental Pathology, Oncology and Radiobiology. RE Kavetsky NAS of Ukraine, Kyiv
  • M.P. Zavelevich Institute of Experimental Pathology, Oncology and Radiobiology. RE Kavetsky NAS of Ukraine, Kyiv
  • S.V. Koval Institute of Experimental Pathology, Oncology and Radiobiology. RE Kavetsky NAS of Ukraine, Kyiv
  • T.S. Ivanovskaya Institute of Experimental Pathology, Oncology and Radiobiology. RE Kavetsky NAS of Ukraine, Kyiv
  • L.Yu. Poludnenko Institute of Experimental Pathology, Oncology and Radiobiology. RE Kavetsky NAS of Ukraine, Kyiv
  • N.I. Ukrainskaya Institute of Experimental Pathology, Oncology and Radiobiology. RE Kavetsky NAS of Ukraine, Kyiv
  • G.D. Тelegeev Institute of Molecular Biology and Genetics, NAS of Ukraine, Kyiv
  • M.V. Dybkov Institute of Molecular Biology and Genetics, NAS of Ukraine, Kyiv
  • L.A. Polischuk Institute of Molecular Biology and Genetics, NAS of Ukraine, Kyiv

DOI:

https://doi.org/10.15407/scin9.06.061

Keywords:

myeloid neoplasms, chronic myelogenous leukemia, polycythemia vera, primary myelofibrosis, essential thrombocythemia, cytomorphological diagnosis, reverse transcriptase polymerase chain reaction.

Abstract

The complex diagnostic system involving cytomorphological, cytochemical, immunocytochemical and molecular genetic study was evaluated and proved to be effective in examining the patients of oncological centers in Ukraine.

References

Swerdlow S.H., Campo E., Harris N.L. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press. 2008. 439 p.

Jaffe E.S., Harris N.L., Stein H., Vardiman Y.W. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press. 2001. 351 p.

Murati A., Brecqueville M., Devillier R. et al. Myeloid malignancies: mutations, models and management. BMC Cancer. 2012. V. 12. P. 304.

https://doi.org/10.1186/1471-2407-12-304

Baxter E.J., Scott L.M., Campbell P.J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myelo proliferative disorders. Lancet. 2005. V. 365, No. 9464. P. 1054-1061.

https://doi.org/10.1016/S0140-6736(05)74230-6

Kralovics R., Passamonti F., Buser A.S. et al. A gain-offunction mutation of JAK2 in myeloproliferative di s orders. N Engl J Med. 2005. V. 352, No. 17. P. 1779-1790.

https://doi.org/10.1056/NEJMoa051113

Zhao R., Xing S., Li Z. et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol. Chem. 2005. V. 280, No. 24. P. 22788-22792.

https://doi.org/10.1074/jbc.C500138200

Levine R.L., Wadleigh M., Cools J. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005. V. 7, No. 4. P. 387–397.

https://doi.org/10.1016/j.ccr.2005.03.023

Dybkov M.V., Gartovs'ka I.R., Telegejev G.D., Maljuta S.S. Rozrobka test-systemy dlja vyjavlennja mutacii' V617F gena jak2 u hvoryh na hronichni mijeloproliferatyvni zahvorjuvannja. Nauka innov. 2009, 5(6):59-63 [in Ukrainian].

https://doi.org/10.15407/scin5.06.059

Published

2024-06-11

Issue

Section

Research and Engineering Innovative Projects of the National Academy of Sciences of Ukraine